Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02537028 · ClinicalTrials.gov registry record · Phase 1
MSC2364447C Phase 1b in Systemic Lupus Erythematosus
A Phase 1 study, sponsored by EMD Serono Research & Development Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02537028 is a Phase 1 study that has completed, run by EMD Serono Research & Development Institute. The registered enrollment target is 24 participants.
The verdict
NCT02537028, a Phase 1 study, has completed, sponsored by EMD Serono Research & Development Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
Interventions
- DRUG Placebo
- DRUG MSC2364447C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2016-10-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02537028
The ClinicalTrials.gov registry entry for NCT02537028 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono Research & Development Institute, which has 81 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02537028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02537028 about?
NCT02537028 is a clinical study titled "MSC2364447C Phase 1b in Systemic Lupus Erythematosus". The primary purpose of this Phase 1b double-blind, randomized, placebo-controlled trial is to evaluate the safety, tolerability, pharmacokinetic (PK), and biological effect of MSC2364447C administered for 4 weeks in systemic lupus erythematosus subjects (SLE).
What is the current status of trial NCT02537028?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-11-30. Estimated completion is 2016-10-04.
What interventions are being tested in trial NCT02537028?
The interventions under investigation include: Placebo (DRUG), MSC2364447C (DRUG).
Who is sponsoring clinical trial NCT02537028?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.